
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is favored because its cloud-based, pay-per-use SaaS model delivers recurring, high-margin revenue while avoiding reimbursement risk, with 2025 revenue of $77.3M growing 19% YoY and adjusted gross margin reaching 74.2%. Its moat is reinforced by a compounding network of roughly 1,000 institutions across 75 countries and more than 2.5M genomic profiles, which supports strong retention, 117% net dollar retention in 1Q26, and rising ASPs. The outlook is further strengthened by deepening U.S. adoption and biopharma traction, including MSK and MD Anderson collaborations, two large U.S. health-system commitments totaling about 60K analyses annually, and 2026 revenue guidance of $92M to $94M.
Bears say
Sophia Genetics is viewed negatively because its core SOPHiA DDM platform appears unable to convert volume growth into strong revenue growth, with 2024 revenue up just 4% despite 11% volume growth, implying a 6-7% decline in revenue per analysis amid biopharma headwinds. The bear case assumes BioPharma DDM remains only about 5% of revenue from 2026 to 2033, limiting total revenue to $441M at peak and leaving adjusted gross margin flat near 70% with little operating leverage. It also remains unprofitable, faces commercial, competitive, cybersecurity, legal, and dilution risks, and the Guardant Health patent dispute adds further uncertainty to its ability to scale efficiently.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares